$9.36
+0.06 (+0.65%)
Last updated: Apr 16, 2026 01:00
Fundamentals Overview
REGENXBIO Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.
Valuation moderate
Risk (Beta)
1.13 — in line vol
BullzEye Analysis
Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Pressures (Sell):
Analyst grade: D+ · Sentiment weakening (1 downgrade) · 3M vs S&P 500: -38.6% · 3M vs Healthcare sector: -31.8%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: D+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 18, Neutral: 3, Outperform: 5, Overweight: 4.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-25.62; current price is $9.36. That’s a -373.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 4.72 |
| P/S (TTM) | 2.83 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 2.38 |
| Quick Ratio (TTM) | 2.38 |
| Cash Ratio (TTM) | 0.29 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -1.14% |
| Gross margin (TTM) | 52.88% |
| Operating margin (TTM) | -94.58% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for RGNX.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-09 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-03-06 |
| Chardan Capital | maintain | Buy | Buy | 2026-02-10 |
| Goldman Sachs | maintain | Neutral | Neutral | 2026-02-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-10 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-02-10 |
| Chardan Capital | maintain | Buy | Buy | 2026-01-29 |
| Stifel | maintain | Buy | Buy | 2025-12-19 |
| Leerink Partners | maintain | Outperform | Outperform | 2025-12-15 |
| Chardan Capital | maintain | Buy | Buy | 2025-11-20 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-07 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-10-07 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-09-08 |
| Chardan Capital | maintain | Buy | Buy | 2025-09-08 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-08-19 |
| RBC Capital | maintain | Outperform | Outperform | 2025-08-08 |
| Chardan Capital | maintain | Buy | Buy | 2025-08-08 |
| Barclays | maintain | Overweight | Overweight | 2025-08-08 |
| Chardan Capital | maintain | Buy | Buy | 2025-06-09 |
| Goldman Sachs | maintain | Neutral | Neutral | 2025-04-17 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-03-21 |
| Chardan Capital | maintain | Buy | Buy | 2025-03-20 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-03-20 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-03-17 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-03-14 |
| Chardan Capital | maintain | Buy | Buy | 2025-03-14 |
| Goldman Sachs | downgrade | Buy | Neutral | 2025-02-11 |
| RBC Capital | maintain | Outperform | Outperform | 2025-01-21 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-01-15 |
| RBC Capital | maintain | Outperform | Outperform | 2024-12-11 |